LEO Pharma launches Enstilar in UK for plaque psoriasis

20 June 2016

Danish privately-held LEO Pharma has launched its psoriasis treatment Enstilar (calcipotriene/betamethasone dipropionate) in the UK.

Enstilar is the first fixed-combination foam spray for the treatment of plaque psoriasis in the UK and comes with the support of strong Phase II and Phase III data, the company noted.

These data show that Enstilar is a more effective topical combination treatment than those currently available and is generally well-tolerated, with more than half of patients in clinical trials experiencing significant visible signs of improvement within four weeks and some patients seeing improvements at one week.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK